{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:19:31Z","timestamp":1762042771590,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973246"],"award-info":[{"award-number":["81973246"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.lfs.2021.120042","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T21:10:24Z","timestamp":1634677824000},"page":"120042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties"],"prefix":"10.1016","volume":"286","author":[{"given":"Xindong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaolei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingpo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weigen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lfs.2021.120042_bb0005","first-page":"731","article-title":"The effect of statins on the occurrence of peptic ulcer","volume":"26","author":"Feng","year":"2015"},{"issue":"11","key":"10.1016\/j.lfs.2021.120042_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1542\/pir.2017-0234","article-title":"Pediatric gastritis, gastropathy, and peptic ulcer disease","volume":"39","author":"Sierra","year":"2018","journal-title":"Pediatr. Rev."},{"key":"10.1016\/j.lfs.2021.120042_bb0015","first-page":"1433","article-title":"Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients\u2013focus on esomeprazole","volume":"8","author":"Tang","year":"2013","journal-title":"Clin. Interv. Aging"},{"issue":"3","key":"10.1016\/j.lfs.2021.120042_bb0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1734-1140(12)70858-7","article-title":"Proton pump (H+\/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats","volume":"64","author":"Pytlik","year":"2012","journal-title":"Pharmacol. Rep."},{"issue":"10 Pt 2","key":"10.1016\/j.lfs.2021.120042_bb0025","first-page":"74S","article-title":"Pharmacologic properties of proton pump inhibitors","volume":"23","author":"Welage","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.lfs.2021.120042_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.phrs.2008.09.016","article-title":"Proton pump inhibitors in GORD an overview of their pharmacology, efficacy and safety","volume":"59","author":"Savarino","year":"2009","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.lfs.2021.120042_bb0035","first-page":"528","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008"},{"issue":"1","key":"10.1016\/j.lfs.2021.120042_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5056\/jnm14152","article-title":"Proton pump inhibitors reduce the size and acidity of the gastric acid pocket","volume":"21","author":"Jo","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"issue":"8","key":"10.1016\/j.lfs.2021.120042_bb0045","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/14740338.2018.1497155","article-title":"A safety review of proton pump inhibitors to treat acid-related digestive diseases","volume":"17","author":"Savarino","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.lfs.2021.120042_bb0050","first-page":"393","article-title":"Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care","volume":"76","author":"Tack","year":"2013","journal-title":"Acta Gastroenterol. Belg."},{"issue":"30","key":"10.1016\/j.lfs.2021.120042_bb0055","first-page":"2108","article-title":"Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of helicobacter pylori infection: a multicenter, randomized, controlled clinical study","volume":"92","author":"Gao","year":"2012","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.lfs.2021.120042_bb0060","first-page":"137","article-title":"High dose versus low dose intravenous pantoprazole in bleeding peptic ulcer: a randomized clinical trial","volume":"6","author":"Masjedizadeh","year":"2014"},{"issue":"7","key":"10.1016\/j.lfs.2021.120042_bb0065","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0149-2918(03)80207-2","article-title":"A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis","volume":"25","author":"Raghunath","year":"2003","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.lfs.2021.120042_bb0070","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/evj.12191","article-title":"A comparison of two doses of omeprazole in the treatment of equine gastric ulcer syndrome: a blinded, randomised, clinical trial","volume":"46","author":"Sykes","year":"2014","journal-title":"Equine Vet. J."},{"issue":"5","key":"10.1016\/j.lfs.2021.120042_bb0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.healun.2010.12.003","article-title":"The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients","volume":"30","author":"Kofler","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.lfs.2021.120042_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejpb.2020.01.015","article-title":"The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors","volume":"149","author":"Shen","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.lfs.2021.120042_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.vascn.2010.10.003","article-title":"Utility of quantitative whole-body autoradiography (QWBA) and imaging mass spectrometry (IMS) by matrix-assisted laser desorption\/ionization (MALDI) in the assessment of ocular distribution of drugs","volume":"63","author":"Drexler","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"6","key":"10.1016\/j.lfs.2021.120042_bb0105","first-page":"441","article-title":"Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient","volume":"22","author":"Takahashi","year":"2007"},{"issue":"5","key":"10.1016\/j.lfs.2021.120042_bb0110","first-page":"452","article-title":"Determination of ilaprazole in beagle plasma and its pharmaeokineties by high performance liquid chromatography-mass spectrometry","volume":"30","author":"Zhou","year":"2012","journal-title":"Se Pu"},{"issue":"1\u20132","key":"10.1016\/j.lfs.2021.120042_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejps.2006.01.007","article-title":"The distribution pattern of radioactivity across different tissues in quantitative whole-body autoradiography (QWBA) studies","volume":"28","author":"Richter","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"issue":"0132","key":"10.1016\/j.lfs.2021.120042_bb0120","first-page":"132","article-title":"Study on physicochemical properties of ilaprazole sodium","volume":"23","author":"Hou","year":"2013","journal-title":"Pharmacy Today"},{"issue":"15","key":"10.1016\/j.lfs.2021.120042_bb0125","doi-asserted-by":"crossref","first-page":"8499","DOI":"10.1021\/jf201796x","article-title":"Investigation on the interaction between ilaprazole and bovine serum albumin without or with different C-ring flavonoids from the viewpoint of food-drug interference","volume":"59","author":"Zhang","year":"2011","journal-title":"J. Agric. Food Chem."},{"issue":"2","key":"10.1016\/j.lfs.2021.120042_bb0130","first-page":"281","article-title":"Treatment pattern and economic burden of refractory gastroesophageal reflux disease patients in Korea","volume":"26","author":"Park","year":"2020"},{"issue":"1\u20133","key":"10.1016\/j.lfs.2021.120042_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.lfs.2021.120042_bb0140","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521010298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521010298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:54:26Z","timestamp":1758401666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521010298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"alternative-id":["S0024320521010298"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.120042","relation":{},"ISSN":["0024-3205"],"issn-type":[{"type":"print","value":"0024-3205"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.120042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120042"}}